• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Epilepsy - Articles and news items

High efficacy & 0 adverse effects in hemp oil study to treat epileptic children

Industry news / 22 March 2017 / Niamh Marriott, Junior Editor

HempMeds Mexico has revealed the positive results of a recent cannabis study conducted on the effects of the Real Scientific Hemp Oil-X…

E is for Epilepsy

Blog / 18 November 2016 / Niamh Louise Marriott, Digital Content Producer

E is for Epilepsy – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research on Epilepsy…

Martindale’s epilepsy oral suspension product approved in 7 European countries

Industry news / 27 October 2016 / Niamh Louise Marriott, Digital Content Producer

Clobazam oral suspension is used principally as an adjunctive therapy for epilepsy with the formulation particularly suitable for children and young adults…

Infantile Spasms

Infantile spasms selected as 4th target indication for Epidiolex

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

GW Pharmaceuticals has selected infantile spasms as the fourth target indication for its Epidiolex orphan paediatric epilepsy development programme…

Aprecia’s 3D-printed Spritam now available in the US

Industry news / 24 March 2016 / Victoria White

Last year, Spritam made history when it became the first prescription drug product approved by the FDA that is manufactured using 3D printing technology…

Infantile Spasms

GW announces positive results for Epidiolex in Dravet syndrome

Industry news / 14 March 2016 / Victoria White

Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo…

Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy

Industry news / 29 February 2016 / Victoria White

UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures…

Eisai presents new data for perampanel at AES 2015

Industry news / 8 December 2015 / Victoria White

New data, presented at AES 2015, show that Eisai’s Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo…

Real world data for eslicarbazepine acetate presented at AES

Industry news / 7 December 2015 / Victoria White

The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate…

First-in-class epilepsy treatment Fycompa launches in the UK

Industry news / 8 July 2015 / Victoria White

Eisai’s Fycompa (perampanel), a once-daily epilepsy treatment that inhibits AMPA receptors, launches in the United Kingdom today…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +